NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 12:11
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,783.34 mln
Float11.02 mln
Earnings Date11/13/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
267
Transformational upside
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
-3.43
Negative equity
ROE
-1,755
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2024 and headquartered in La Jolla, California, Inhibrx Biosciences is an early-stage company focused on creating new medicines for patients facing serious and life-threatening diseases. The company is advancing two key treatments through clinical trials: one targeting a rare form of bone cancer that cannot be surgically removed, and another aimed at several types of advanced solid tumors including lung cancer, melanoma, and kidney cancer. Both treatments are designed using specialized biological approaches intended to more precisely engage the body's own systems to fight disease.
